Our test consists of a non-invasive plasma-based test designed to achieve performance superiority with respect to state-of-the-art diagnostic tools currently available for prediction of cognitive decline before any symptoms of dementia arise and of ẞ-Amyloid pathological burden (Amyloid PET)

Why is such a test needed now?

Diagnosis in clinical practice takes two years from symptom detection to results, only for an high percentage of patients to end up misdiagnosed. The optimal therapeutic window is within the prodromal stage of the disease. However, no accepted biomarker can be easily used alone, as of today, to predict future Alzheimer patients within a reasonably long observational window. As a result the majority of AD patients are not diagnosed at a stage where currently and future available drugs are most effective.